Expertise in
26
conditions

Dr. Mitchell L. Shiffman

Transplant Surgery | Hepatology
5855 Bremo Road, Suite 509, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Expertise in
26
conditions
5855 Bremo Road, Suite 509, 
Richmond, VA 

Overview

I joined Bon Secours Liver Institute in 2010, and am proud to work with teams in Hampton Roads and Richmond in the care of our patients with liver disease including Hepatitis C, Hepatitis B, fatty liver disease, primary biliary liver cirrhosis, primary sclerosing cholangitis, cirrhosis, non-alcoholic steatohepatitis (NASH), liver cancer, and others. We also care for patients before and after transplantation.

Dr. Shiffman is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Primary Biliary Cholangitis, Hepatitis, Endoscopy, and Liver Transplant.

Dr. Shiffman is board certified in (Internal Medicine), American Board Of Internal Medicine, and (Internal Medicine, Gastroenterology). He is actively involved in clinical research, co-authoring 103 peer reviewed articles and participating in 25 clinical trials. Dr. Shiffman is currently accepting new patients.

Specialties

Transplant Surgery
Hepatology

Licenses

Internal Medicine in VA

Board Certifications

(Internal Medicine)
American Board Of Internal Medicine
(Internal Medicine, Gastroenterology)

Fellowships

Medical College Of Virginia Hospitals, Gastroenterology - 1989

Hospital Affiliations

Bon Secours Richmond Community Hospital
Bon Secours - St. Mary's Hospital
Mary Immaculate Hospital
Bon Secours St Francis Medical Center
Bon Secours Richmond Community Hospital
Bon Secours Memorial Regional Medical Center
Bon Secours St Marys Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Bon Secours Liver Institute of Richmond
5855 Bremo Road, Suite 509, Richmond, VA 23226

Additional Areas of Focus

Dr. Shiffman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
Enrollment Status: Completed
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: HTD1801 (BUDCA)
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Completed
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: February 18, 2026
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Combination product
Study Phase: Not Applicable
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
View 9 Less Clinical Trials

103 Total Publications

Letter: FDA Approval of the HepQuant SHUNT Liver Diagnostic Test and Clarification of the SHUNT-V Analysis Cohort.
Letter: FDA Approval of the HepQuant SHUNT Liver Diagnostic Test and Clarification of the SHUNT-V Analysis Cohort.
Journal: Alimentary pharmacology & therapeutics
Published: July 24, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Richard T. Stravitz
Transplant Surgery
Expertise in
15
conditions
Dr. Richard T. Stravitz
Transplant Surgery
Referral may be required

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (5.4 miles away)
828-406-0804
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Richard Stravitz is a Transplant Surgeon practicing medicine in Richmond, Virginia. Dr. Stravitz is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Liver Failure, Hepatitis, Hepatitis C, Autoimmune Hepatitis, and Liver Transplant. Dr. Stravitz is currently accepting new patients.

Expertise in
15
conditions
Sarah B. Hubbard, PA
Transplant Surgery | Hepatology
Expertise in
15
conditions
Sarah B. Hubbard, PA
Transplant Surgery | Hepatology
Referral may be required

Bon Secours Liver Institute Of Richmond

5855 Bremo Road, Suite 509, 
Richmond, VA 
 (0.1 miles away)
804-977-8920
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I began my interest in healthcare as a Peace Corps volunteer in Morocco. Since becoming a PA in 1999, I've been focused in the management of liver disease. I've been amazed to see the advances in care within this field. I joined Dr. Mitchell Shiffman at Bon Secours Liver Institute of Richmond in January of 2015 and enjoy building relationships with our patients. I enjoy spending time with my family, travel as often as possible and love to sew!. Dr. Hubbard is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Visceromegaly, Enlarged Liver, Primary Biliary Cholangitis, and Reynolds Syndrome. Dr. Hubbard is board certified in National Commission On Certification Of Physician Assistants and (Physician Assistant). Dr. Hubbard is currently accepting new patients.

Expertise in
4
conditions
Expertise in
4
conditions
Referral may be required

Department Of Veteran Affairs

1201 Broad Rock Blvd, 
Richmond, VA 
 (6.4 miles away)
804-675-5021
Languages Spoken:
English

Douglas Heuman is a Hepatologist practicing medicine in Richmond, Virginia. Dr. Heuman is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Liver Failure, Cirrhosis, Alcoholic Cirrhosis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

Frequently Asked Questions about Dr. Mitchell L. Shiffman

How do I make an appointment with Dr. Mitchell L. Shiffman?

You can book an appointment with Dr. Mitchell L. Shiffman by calling their office at 804-977-8920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mitchell L. Shiffman a top-rated expert for Hepatitis C?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mitchell L. Shiffman is classified as an Elite expert for Hepatitis C, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mitchell L. Shiffman specialize in?

While Dr. Mitchell L. Shiffman is a Transplant Surgery, they have specific expertise in Hepatitis C, Primary Biliary Cholangitis, and Hepatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Transplant Surgery.

Does Dr. Mitchell L. Shiffman participate in research or clinical trials?

Yes. Dr. Mitchell L. Shiffman has published 103 articles and abstracts on conditions like Hepatitis C. You can view a list of Dr. Mitchell L. Shiffman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mitchell L. Shiffman accept my insurance?

Dr. Mitchell L. Shiffman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-977-8920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shiffman's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 12 Distinguished Conditions
View All 7 Advanced Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile